X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs SANOFI INDIA - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA SANOFI INDIA FULFORD INDIA/
SANOFI INDIA
 
P/E (TTM) x 398.8 40.1 995.1% View Chart
P/BV x 6.2 8.6 71.9% View Chart
Dividend Yield % 0.1 1.0 8.1%  

Financials

 FULFORD INDIA   SANOFI INDIA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
SANOFI INDIA
Dec-16
FULFORD INDIA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs9424,560 20.7%   
Low Rs4504,400 10.2%   
Sales per share (Unadj.) Rs691.41,028.5 67.2%  
Earnings per share (Unadj.) Rs11.5129.0 8.9%  
Cash flow per share (Unadj.) Rs15.4186.0 8.3%  
Dividends per share (Unadj.) Rs2.0068.00 2.9%  
Dividend yield (eoy) %0.31.5 18.9%  
Book value per share (Unadj.) Rs380.0753.6 50.4%  
Shares outstanding (eoy) m3.9023.03 16.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.04.4 23.1%   
Avg P/E ratio x60.734.7 174.8%  
P/CF ratio (eoy) x45.324.1 188.1%  
Price / Book Value ratio x1.85.9 30.8%  
Dividend payout %17.452.7 33.1%   
Avg Mkt Cap Rs m2,714103,174 2.6%   
No. of employees `0000.43.6 12.3%   
Total wages/salary Rs m5053,592 14.1%   
Avg. sales/employee Rs Th6,073.06,537.7 92.9%   
Avg. wages/employee Rs Th1,137.4991.4 114.7%   
Avg. net profit/employee Rs Th100.7819.8 12.3%   
INCOME DATA
Net Sales Rs m2,69623,686 11.4%  
Other income Rs m125708 17.7%   
Total revenues Rs m2,82224,394 11.6%   
Gross profit Rs m-465,281 -0.9%  
Depreciation Rs m151,313 1.2%   
Interest Rs m1015 63.3%   
Profit before tax Rs m544,661 1.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m101,691 0.6%   
Profit after tax Rs m452,970 1.5%  
Gross profit margin %-1.722.3 -7.7%  
Effective tax rate %17.736.3 48.7%   
Net profit margin %1.712.5 13.2%  
BALANCE SHEET DATA
Current assets Rs m1,73815,673 11.1%   
Current liabilities Rs m5456,678 8.2%   
Net working cap to sales %44.338.0 116.6%  
Current ratio x3.22.3 136.0%  
Inventory Days Days4876 63.8%  
Debtors Days Days422 19.3%  
Net fixed assets Rs m128,098 0.1%   
Share capital Rs m39230 16.9%   
"Free" reserves Rs m1,44317,088 8.4%   
Net worth Rs m1,48217,356 8.5%   
Long term debt Rs m00-   
Total assets Rs m2,07725,400 8.2%  
Interest coverage x6.7311.7 2.2%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.9 139.2%   
Return on assets %2.611.8 22.2%  
Return on equity %3.017.1 17.6%  
Return on capital %4.326.9 16.0%  
Exports to sales %024.5 0.0%   
Imports to sales %24.528.0 87.4%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs m6596,627 9.9%   
Fx inflow Rs m177,145 0.2%   
Fx outflow Rs m6736,846 9.8%   
Net fx Rs m-656299 -219.4%   
CASH FLOW
From Operations Rs m903,226 2.8%  
From Investments Rs m105-1,555 -6.7%  
From Financial Activity Rs m-14-1,818 0.8%  
Net Cashflow Rs m181-147 -122.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 60.4 124.2%  
Indian inst/Mut Fund % 3.8 14.4 26.4%  
FIIs % 0.1 14.6 0.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 10.5 201.9%  
Shareholders   4,783 15,184 31.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   MERCK LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  IPCA LABS  

Compare FULFORD INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note; Banking and Healthcare Stocks Witness Buying Interest(Closing)

Indian share markets ended their session on a positive note today. Gains were largely seen in the banking sector and healthcare sector.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - ELDER PHARMA COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS